美国注射吸毒者网络中丙肝联合治疗与预防策略的建模研究
该建模研究基于美国哈特福德市1574名注射吸毒者的实证数据,模拟注射网络并评估丙肝治疗作为预防(TasP)联合阿片 agonist 治疗(OAT)和针具服务项目(SSP)扩大的效果。结果显示,在丙肝高流行(75%)时,OAT覆盖率从10%升至40%并结合每年10%的丙肝治疗及SSP扩大至40%,可使微消除时间从18.4年缩短至11.6年;在现有流行率(60%)下,每年10%的TasP即可在10年内实现微消除,而OAT扩大的额外影响有限。
要点
- 丙肝TasP扩大是微消除最有效策略。
- 丙肝流行率超过60%且治疗覆盖率≤10/100人年时,OAT扩大有协同作用。
- 流行率≤60%时,大规模初始治疗策略最有效。
核心结论
- 扩大丙肝TasP是实现丙肝微消除的最有效策略。
- 当丙肝流行率超过60%且每年治疗覆盖率为10/100注射吸毒者或更低时,OAT扩大可能对实现微消除目标有协同作用。
研究设计与样本
- 使用美国康涅狄格州哈特福德的实证数据,部署随机块模型模拟1574名注射吸毒者的注射网络。
- 采用易感-感染模型评估丙肝和艾滋病病毒,比较多种丙肝TasP策略(包括联合OAT和SSP扩大)在20年内的效果。
主要发现
- 在最高丙肝流行率(75%)下,OAT覆盖率从10%增至40%,联合每年10%的丙肝治疗及SSP扩大至40%,微消除时间从18.4年缩短至11.6年。
- 在当前丙肝流行率(60%)下,每年低至10%覆盖率的丙肝TasP策略可在10年内实现微消除,而额外OAT扩大的影响最小。
- 基于大规模初始丙肝治疗(第一年每100名注射吸毒者治疗50人,之后每年每100人治疗5人)的策略在丙肝流行率60%或更低时最有效。
临床怎么用
- 在丙肝高流行(>60%)且治疗覆盖率低的注射吸毒者网络中,应优先扩大丙肝TasP并考虑同步扩大OAT以加速微消除。
- 在丙肝流行率≤60%时,可优先实施大规模初始丙肝治疗策略,OAT扩大的额外收益有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis C virus (HCV) treatment as prevention (TasP) strategies can contribute to HCV microelimination, yet complimentary interventions such as opioid agonist therapies (OAT) with methadone or buprenorphine and syringe services programs (SSPs) may improve the prevention impact. This modeling study estimates the impact of scaling up the combination of OAT and SSPs with HCV TasP in a network of people who inject drugs (PWID) in the United States. METHODS: Using empirical data from Hartford, Connecticut, we deployed a stochastic block model to simulate an injection network of 1574 PWID. We used a susceptible-infected model for HCV and human immunodeficiency virus to evaluate the effectiveness of several HCV TasP strategies, including in combination with OAT and SSP scale-up, over 20 years. RESULTS: At the highest HCV prevalence (75%), when OAT coverage is increased from 10% to 40%, combined with HCV treatment of 10% per year and SSP scale up to 40%, the time to achieve microelimination is reduced from 18.4 to 11.6 years. At the current HCV prevalence (60%), HCV TasP strategies as low as 10% coverage per year may achieve HCV microelimination within 10 years, with minimal impact from additional OAT scale-up. Strategies based on mass initial HCV treatment (50 per 100 PWID the first year followed by 5 per 100 PWID thereafter) were most effective in settings with HCV prevalence of 60% or lower. CONCLUSIONS: Scale-up of HCV TasP is the most effective strategy for microelimination of HCV. OAT scale-up, however, scale-up may be synergistic toward achieving microelimination goals when HCV prevalence exceeds 60% and when HCV treatment coverage is 10 per 100 PWID per year or lower.
引用
- Zelenev A, Li J, Shea P, et al. Modeling Combination Hepatitis C Virus Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the United States. Clin Infect Dis. 2021. PMID: 32060534. doi:10.1093/cid/ciaa142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。